您现在的位置是:首页>权威专家> 肾癌

Ulka Vaishampayan M.D

Ulka Vaishampayan M.D

所在科室:外科

就职医院:Karmanos cancer center

医生擅长:

在线咨询医学顾问 电话热线:400-666-7998

医生介绍

 ·         Gender

·         Female

·         Multidisciplinary Team(s)

·         Genitourinary Oncology 
Phase 1 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Adrenal Cancer 
Bladder cancer 
Kidney Cancer 
Prostate Cancer 
Testicular Cancer 

·         Contact Info

·         Email:
vaishamu@karmanos.org

          Education

·         Fellowship
Hematology/oncology Fellowship, Wayne State University, Detroit, MI
Fellowship
Chief Fellow, Hematology/Oncology, Wayne State University, Detroit, MI
Medical School
Byramjee Jeejeebhoy Medical School
Residency
Residency in Medicine, Wayne State University, Detroit, Michigan

·         Professional Memberships/Associations

·         American Society of Clinical Oncology 
Southwest oncology Group 

·         Board Certifications

·         American Board of Medical Oncology

·         Clinical Interests

·         Medical Oncology 

·         Research Interests

·         Reaserch related to clinical trials in prostate, kidney and bladder cancers, overcoming resistance to current therapies and exploring novel treatments and combinations in prostate cancer, as well as development of prognostic and predictive markers in kidney cancer 

·         Profile

·         Dr. Vaishampayan has been providing patient care on staff at Karmanos since 2000. Her experience extends to research, as well as being a member of the editorial board for multiple oncology journal. In addition, she is a lecturer and educator at Wayne State University School of Medicine.

·         Awards

·         Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year

·         Publications

·         Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4;368(14):1314-25 PMID:23550669. Authors: Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, et al.
Phase II trial of satraplatin and bevacizumab in metastatic docetaxel pretreated castrate resistant prostate cancer. Urol Oncol. 2013 Feb 20. S1078-1439. PMID:23433892. Authors: Vaishampayan U, Heilbrun L, Smith D, Baranowski K, Dickow B, Figg W.
External Validation and Comparison with Other Models of the International metastatic Renal-Cell Carcinoma Database Consortium Prognostic Model: A Population-based Study. Lancet oncol 2013 Feb;14(2):141-148. Doi: 10.1016/S1470-2045(12)70559-4. Epub 2013 Jan 98. PMID:23312463. Authors: Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N. Kollmannsberger C, Rini BI, Choueiri TK.
The Association of Clinical Outcome to First-line VEGF-Targeted Therapy with Clinical Outcome to Second-line VEGF-Targeted Therapy in metastatic Renal Cell Carcinoma Patients. For the International mRCC Database Consortium. Target Oncol. 2013 Jan 9. PMID:23300029. Authors: Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha Sy, Donskov FN, North S, Coueiri TK, Heng DY;
Cabozantinib as a Novel Therapy for Renal Cell Carcinoma. Curr oncol Rep. 2013 Jan 5. [Epub ahead of print] PMID:232929795]. Author: Vaishampayan U.

相关报道资讯

视频科普

胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医
胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医

简介: 胃癌IV期伴有肝脏及肝胃间隙淋巴结转移,国内无标准方案,会诊得知这里胃癌5年生存率相比要高。习惯了家里的医院,还真不适应... 更多»

大肠癌伴肝转移患者赴日就医
大肠癌伴肝转移患者赴日就医

简介:大肠癌伴肝转移,本想国内治疗,但通过日ben癌研有明医院在线会诊,家人支持来院手术。非常顺利4小时完成切除和淋巴结清扫,第二... 更多»

胶质母细胞瘤和髓母细胞瘤患者赴日就医
胶质母细胞瘤和髓母细胞瘤患者赴日就医

简介: 你经历过绝望到希望吗?在国内先后被诊断为胶质母细胞瘤和髓母细胞瘤的患者。术后只做了脑部放疗,复发了。最后参加了日ben国... 更多»

肝癌患者日本国际就医案例
肝癌患者日本国际就医案例

简介: 肝癌,多年前在日ben癌研有明病院做的手术,这次来复查,结果很满意,但是还需3个月后再次复查,6月份再来,明日回国,感谢帮... 更多»

癌症患者的新方案来了!数十位国际专家带先进技术助力国内癌症患者
癌症患者的新方案来了!数十位国际专家带先进技术助力国内癌症患者

简介:癌症患者的新方案来了!数十位国际专家带先进技术助力国内癌症患者... 更多»

在线预约

绿色快速预约通道

Ulka Vaishampayan M.D

请正确填写预约人和联系人等信息,提交需求成功后,请保持联系电话畅通,客服会在48小时内与您联系确认信息。客服热线:400-666-7998

Ulka Vaishampayan M.D

Karmanos cancer center 外科

擅长

简介

 ·         Gender

·         Female

·         Multidisciplinary Team(s)

·         Genitourinary Oncology 
Phase 1 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Adrenal Cancer 
Bladder cancer 
Kidney Cancer 
Prostate Cancer 
Testicular Cancer 

·         Contact Info

·         Email:
vaishamu@karmanos.org

          Education

·         Fellowship
Hematology/oncology Fellowship, Wayne State University, Detroit, MI
Fellowship
Chief Fellow, Hematology/Oncology, Wayne State University, Detroit, MI
Medical School
Byramjee Jeejeebhoy Medical School
Residency
Residency in Medicine, Wayne State University, Detroit, Michigan

·         Professional Memberships/Associations

·         American Society of Clinical Oncology 
Southwest oncology Group 

·         Board Certifications

·         American Board of Medical Oncology

·         Clinical Interests

·         Medical Oncology 

·         Research Interests

·         Reaserch related to clinical trials in prostate, kidney and bladder cancers, overcoming resistance to current therapies and exploring novel treatments and combinations in prostate cancer, as well as development of prognostic and predictive markers in kidney cancer 

·         Profile

·         Dr. Vaishampayan has been providing patient care on staff at Karmanos since 2000. Her experience extends to research, as well as being a member of the editorial board for multiple oncology journal. In addition, she is a lecturer and educator at Wayne State University School of Medicine.

·         Awards

·         Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year

·         Publications

·         Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4;368(14):1314-25 PMID:23550669. Authors: Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, et al.
Phase II trial of satraplatin and bevacizumab in metastatic docetaxel pretreated castrate resistant prostate cancer. Urol Oncol. 2013 Feb 20. S1078-1439. PMID:23433892. Authors: Vaishampayan U, Heilbrun L, Smith D, Baranowski K, Dickow B, Figg W.
External Validation and Comparison with Other Models of the International metastatic Renal-Cell Carcinoma Database Consortium Prognostic Model: A Population-based Study. Lancet oncol 2013 Feb;14(2):141-148. Doi: 10.1016/S1470-2045(12)70559-4. Epub 2013 Jan 98. PMID:23312463. Authors: Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N. Kollmannsberger C, Rini BI, Choueiri TK.
The Association of Clinical Outcome to First-line VEGF-Targeted Therapy with Clinical Outcome to Second-line VEGF-Targeted Therapy in metastatic Renal Cell Carcinoma Patients. For the International mRCC Database Consortium. Target Oncol. 2013 Jan 9. PMID:23300029. Authors: Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha Sy, Donskov FN, North S, Coueiri TK, Heng DY;
Cabozantinib as a Novel Therapy for Renal Cell Carcinoma. Curr oncol Rep. 2013 Jan 5. [Epub ahead of print] PMID:232929795]. Author: Vaishampayan U.

TA的文章视频